Pages that link to "Item:Q4559685"
From MaRDI portal
The following pages link to A Bayesian Phase I/II Trial Design for Immunotherapy (Q4559685):
Displaying 9 items.
- Biomarker-based precision dose finding for immunotherapy combined with radiotherapy (Q6572286) (← links)
- A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages (Q6572291) (← links)
- DROID: dose-ranging approach to optimizing dose in oncology drug development (Q6589229) (← links)
- REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors (Q6618357) (← links)
- A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications (Q6622241) (← links)
- A Bayesian design for phase I cancer therapeutic vaccine trials (Q6625928) (← links)
- BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint (Q6626777) (← links)
- Hybrid design evaluating new biomarkers when there is an existing screening test (Q6627744) (← links)
- A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials (Q6627894) (← links)